Enanta Pharmaceuticals | ENTA - Selling And Administration Expenses


Enanta Pharmaceuticals reported $-1.05 in Selling and Administration Expenses for its fiscal quarter ending in December of 2024.





Selling And Administration Expenses Change Date
AbbVie USD 3.58B 316M Mar/2026
Amgen USD 1.58B 354M Mar/2026
Anika Therapeutics USD 10.01M 14K Dec/2025
Arrowhead Research USD 46.02M 8.84M Dec/2025
AstraZeneca USD 5.06B 455M Mar/2026
BioCryst Pharmaceuticals USD 95.78M 12.77M Dec/2025
Biogen USD 554.3M 128.2M Mar/2026
Bristol-Myers Squibb USD 1.62B 564M Mar/2026
Enanta Pharmaceuticals USD -1.05 0.31 Dec/2024
Gilead Sciences USD 1.78B 425M Dec/2025
GlaxoSmithKline GBP 2.12B 558M Mar/2026
Halozyme Therapeutics USD 64.64M 27.11M Dec/2025
Heron Therapeutics USD 23.74M 605K Dec/2025
Immunic USD 3.45M 451K Dec/2025
Incyte USD 328.1M 62.31M Mar/2026
Insmed USD 212.48M 26.11M Dec/2025
Ionis Pharmaceuticals USD 151M 21M Mar/2026
J&J USD 6.03B 719M Mar/2026
Karyopharm Therapeutics USD 9.56M 17.63M Dec/2025
Ligand Pharmaceuticals USD 28.45M 8.27M Sep/2025
Merck USD 2.67B 180M Mar/2026
Neurocrine Biosciences USD 301.8M 10.2M Dec/2025
Novartis USD 3.14B 296M Mar/2026
Novavax USD 25.53M 1.34M Dec/2025
Pfizer USD 4.08B 894M Dec/2025
PTC Therapeutics USD 87.2M 3.15M Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
Sarepta Therapeutics USD 105.38M 28.27M Dec/2025
Vertex Pharmaceuticals USD 493.7M 6.7M Mar/2026